{
  "source": "PA-Notification-Valchlor.txt",
  "chunks": [
    "UnitedHealthcare Pharmacy\nClinical Pharmacy Programs\nProgram Number 2024 P 1123-13\nProgram Prior Authorization/Notification\nMedication Valchlor® gel for topical use (mechlorethamine)\nP&T Approval Date 4/2014, 11/2014, 11/2015, 9/2016, 9/2017, 9/2018, 9/2019, 9/2020,\n10/2021, 10/2022, 10/2023, 10/2024\nEffective Date 1/1/2025\n1. Background:\nValchlor gel for topical use (mechlorethamine) is an alkylating drug indicated for the topical\ntreatment of Stage IA and IB mycosis fungoides-type cutaneous T-cell lymphoma in patients\nwho have received prior skin-directed therapy.1 The National Cancer Comprehensive Network\n(NCCN) recommends use of topical mechlorethamine in T-cell leukemia/lymphoma, primary\ncutaneous B-cell lymphoma, primary cutaneous CD30+ T-cell lymphoproliferative disorders,\nand Langerhans Cell Histiocytosis (LCH).2\nCoverage Information:\nMembers will be required to meet the criteria below for coverage. For members under the age of\n19 years, the prescription will automatically process without a coverage review.\nSome states mandate benefit coverage for off-label use of medications for some diagnoses or\nunder some circumstances. Some states also mandate usage of other Compendium references.\nWhere such mandates apply, they supersede language in the benefit document or in the\nnotification criteria.\n2. Coverage Criteriaa:\nA. Patients less than 19 years of age\n1. Valchlor will be approved based on the following criterion:\na. Patient is less than 19 years of age\nAuthorization will be issued for 12 months.\nB. Primary Cutaneous Lymphomas\n1. Initial Authorization\na. Valchlor will be approved based on the following criteria:\n(1) Diagnosis of one of the following:\n(a) Chronic or smoldering T-cell leukemia/lymphoma\n(b) Primary cutaneous marginal zone or follicle center B-cell lymphoma\n(c) Lymphomatoid papulosis (LyP) with extensive lesions\n(d) Mycosis fungoides (MF)/Sezary syndrome (SS)\n© 2024 UnitedHealthcare Services, Inc.\n1\nAuthorization will be issued for 12 months.\n2. R",
    "mphoma\n(c) Lymphomatoid papulosis (LyP) with extensive lesions\n(d) Mycosis fungoides (MF)/Sezary syndrome (SS)\n© 2024 UnitedHealthcare Services, Inc.\n1\nAuthorization will be issued for 12 months.\n2. Reauthorization\na. Valchlor will be approved based on the following criterion:\n(1) Patient does not show evidence of progressive disease while on Valchlor\nAuthorization will be issued for 12 months.\nC. Histiocytic Neoplasms\n1. Initial Authorization\na. Valchlor will be approved based on both of the following criteria:\n(1) Diagnosis of Langerhans Cell Histiocytosis (LCH)\n-AND–\n(2) Skin disease is unifocal and isolated\nAuthorization will be issued for 12 months.\n2. Reauthorization\na. Valchlor will be approved based on the following criterion:\n(1) Patient does not show evidence of progressive disease while on Valchlor\nAuthorization will be issued for 12 months.\nD. NCCN Recommended Regimens\nThe drug has been recognized for treatment of the cancer indication by The National\nComprehensive Cancer Network (NCCN) Drugs and Biologics Compendium with a\nCategory of Evidence and Consensus of 1, 2A, or 2B\nAuthorization will be issued for 12 months.\na State mandates may apply. Any federal regulatory requirements and the member specific\nbenefit plan coverage may also impact coverage criteria. Other policies and utilization\nmanagement programs may apply\n3. Additional Clinical Rules:\n• Notwithstanding Coverage Criteria, UnitedHealthcare may approve initial and re-\nauthorization based solely on previous claim/medication history, diagnosis codes (ICD-10)\n© 2024 UnitedHealthcare Services, Inc.\n2\nand/or claim logic. Use of automated approval and re-approval processes varies by\nprogram.\n• Supply limits may be in place.\n4. References:\n1. Valchlor [package insert]. South San Francisco, CA: Actelion Pharmaceuticals US, Inc.;\nJanuary 2020.\n2. The NCCN Drugs and Biologics Compendium (NCCN Compendium™). Available at\nhttps://www.nccn.org/compendia-templates/compendia/drugs-and-biologics-compendia.\nAcc",
    "harmaceuticals US, Inc.;\nJanuary 2020.\n2. The NCCN Drugs and Biologics Compendium (NCCN Compendium™). Available at\nhttps://www.nccn.org/compendia-templates/compendia/drugs-and-biologics-compendia.\nAccessed September 11, 2024.\nProgram Prior Authorization/Notification - Valchlor gel for topical use\n(mechlorethamine)\nChange Control\n4/2014 New criteria.\n9/2014 Administrative change - Tried/Failed exemption for State of New Jersey\nremoved.\n11/2014 Annual review. Updated references.\n11/2015 Annual review. Added additional NHL indications to coverage criteria\nand updated MF/SS criteria. Updated background & references.\n9/2016 Annual review. Updated references.\n9/2017 Annual review. Updated criteria for mycosis fungoides/sezary\nsyndrome. Updated references.\n9/2018 Annual review. Updated criteria based on NCCN Compendium.\nUpdated references.\n9/2019 Annual review. Renamed NHL to Primary Cutaneous Lymphomas.\nRevised coverage rationale based on NCCN Compendium. Updated\nreferences. Added general NCCN recommended review criteria.\n9/2020 Annual review. No changes to coverage criteria.\n10/2021 Annual review. Added coverage rationale for LCH according to NCCN\nCompendium. Updated references.\n10/2022 Annual review. No changes to coverage criteria. Added state mandate.\nUpdated references.\n10/2023 Annual review. No changes to coverage criteria. Updated references.\n10/2024 Annual review. No changes to coverage criteria. Updated references.\n© 2024 UnitedHealthcare Services, Inc.\n3"
  ]
}